XML 41 R26.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Escrow Shares remaining   17,414
Cash balances $ 20,664,410 $ 8,696,361
Cash held in financial institutions 20,287,212 8,160,271
In-Process Research & Development 154,824,000  
Goodwill 11,640,000 11,640,000
Research and development expense $ 15,538,122 $ 4,694,349
Common Stock outstanding 52,219,661 46,497,409
Potential dilutive shares 4,011,653 4,091,686
Common stock shares issued 18,081,962  
Fair value $ 21,516,000  
Contingent shares issuable 1,350,000  
Stock price per share $ 4.97  
Warrants exercise price $ 1.30  
Risk-free rate 0.08%  
Expected volatility rate 79.20%  
Digital call rate 90.00%  
Stock-based compensation $ 1,297,798 $ 884,724
Common Stock [Member]    
Stock-based compensation  
Stock issued in exchange for services, Shares 35,000 30,000
Stock issued in exchange for services, Value $ 147,000 $ 144,000
Employee [Member]    
Stock-based compensation $ 1,444,798 $ 1,028,724
Enochian Biopharma Inc. [Member]    
Common shares contingently issuable 1,350,000 1,438,122